Breast cancer drug rejected for NHS use on cost-benefit grounds

Charities angered by guidance on Kadcyla, which costs £90,000 per year per patient and gives extra nine months on average

A breast cancer drug that costs £90,000 a year per patient has been turned down for use by the NHS on financial grounds, triggering an outcry from patients groups who say it prolongs the lives of people seriously ill with the disease.

Kadcyla, made by Roche Pharmaceuticals, was rejected by the National Institute for Health and Care Excellence. It has the highest price tag ever for a cancer medicine and was turned down because its benefits did not justify its cost, Nice said.

Continue reading…

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us